...
首页> 外文期刊>Journal of cardiovascular electrophysiology >Caveat emptor: implantable devices in end-stage renal disease.
【24h】

Caveat emptor: implantable devices in end-stage renal disease.

机译:告诫者:用于终末期肾脏疾病的可植入装置。

获取原文
获取原文并翻译 | 示例

摘要

Cardiovascular disease is the leading cause of mortality in patients, with chronic kidney disease (CKD) accounting for more than half of all deaths in this population. Even a modest decrease in renal function has been identified as a powerful, independent risk factor for cardiovascular death. In addition, more than 400,000 people in the United States have end-stage renal disease (ESRD) requiring dialysis therapy, with some estimates predicting more than 2 million people by the year 2030. The prognosis for these individuals is poor, with mortality rates in excess of 20% during the first year of dialysis. Cardiac disease remains the major cause of death in patients with ESRD, accounting for 43 % of all-cause mortality. Furthermore, 61% of all cardiac deaths and 26% of all deaths in ESRD patients are presumed to be arrhythmic in etiology. The mortality rate for dialysis patients who survive sudden cardiac death is 85% at 1 year.
机译:心血管疾病是患者死亡的主要原因,慢性肾脏病(CKD)占该人群全部死亡的一半以上。甚至肾功能的轻度下降也被确定为心血管死亡的强大独立危险因素。此外,美国有超过40万人患有需要透析治疗的终末期肾病(ESRD),据估计,到2030年,将有超过200万人。这些人的预后很差,死亡率很高。在透析的第一年中超过20%。心脏疾病仍然是ESRD患者死亡的主要原因,占全因死亡率的43%。此外,ESRD患者的所有心脏死亡中的61%和所有死亡中的26%被认为是病因不完整。存活于心脏猝死的透析患者在1年时的死亡率为85%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号